Innovative funding models like value-based payments can change providers’ incentives and drive them to seek solutions like palliative care, said Allison Silvers, vice president of payment and policy at the Center to Advance Palliative Care.
Innovative funding models like value-based payments can change providers’ incentives and drive them to seek solutions like palliative care, said Allison Silvers, vice president of payment and policy at the Center to Advance Palliative Care.
Transcript (slightly modified)
How can innovative funding models drive transformation in organization operations?
I think there’s 2 parts to that. The first is innovative funding changes the incentives that providers operate under. Using that example of COPD [chronic obstructive pulmonary disease], pulmonologists might be driven to produce certain outcomes and certain costs within a framework that they wouldn’t have otherwise been responsible for. So they’re going to be looking for solutions, and that’s where innovative funding really helps palliative care, because palliative care is an important solution to what they’re trying to achieve.
Innovative funding as value funding—making sure that costs are within targets and making sure that patient experience is within certain, I would think very high, parameters; certain quality metrics are achieved—all of that can be helped with palliative care. So it maybe is even not so much how you pay for the palliative care, but how you pay the treating providers could drive a demand for palliative care integration.
Humana Report Shows Benefits of Value-Based Care for Patients, Physicians
December 6th 2023Patients seen at value-based care clinics received more preventive screenings and had lower risks of hospitalization and emergency room visits, according to Humana’s 10th annual value-based care report.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab for Treating COPD, Type 2 Inflammation
December 4th 2023Patients with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation had significantly better lung function at least a year into a dupilumab regimen.
Read More